-
Glaukos Has 84% Upside Potential In 2018, According To Cantor
Wednesday, December 27, 2017 - 2:48pm | 447Glaukos Corp (NYSE: GKOS) announced the submission of a pre-market approval application for its iStent inject device on Wednesday. The Analyst Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Glaukos' stock with a price target boosted from $48 to $60. The Thesis...